IMJUDO Concentrate for solution for infusion Ref.[50776] Active ingredients: Tremelimumab

Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: AstraZeneca AB, SE-151 85 Södertälje, Sweden

Product name and form

IMJUDO 20 mg/ml concentrate for solution for infusion.

Pharmaceutical Form
Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles. The solution has a pH of approximately 5.5 and an osmolality of approximately 285 mOsm/kg.

Qualitative and quantitative composition

Each mL of concentrate for solution for infusion contains 20 mg of tremelimumab.

One vial of 1.25 ml of concentrate contains 25 mg of tremelimumab.

One vial of 15 ml of concentrate contains 300 mg of tremelimumab.

Tremelimumab is a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunoglobulin G2 IgG2a monoclonal antibody produced in murine myeloma cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient	Description
Tremelimumab	Tremelimumab is a selective, fully human IgG2 antibody that blocks CTLA-4 interaction with CD80 and CD86, thus enhancing T-cell activation and proliferation, resulting in increased T-cell diversity and enhanced antitumour activity. Cytotoxic T lymphocyte-associated antigen (CTLA-4) is primarily expressed on the surface of T lymphocytes.

List of Excipients
Histidine Histidine hydrochloride monohydrate Trehalose dihydrate Disodium edetate dihydrate Polysorbate 80 Water for injections

Pack sizes and marketing

Two pack sizes of IMJUDO are available:

1.25 ml (a total of 25 mg tremelimumab) concentrate in a Type I glass vial with an elastomeric stopper and a violet flip-off aluminum seal. Pack size of 1 single-dose vial.
15 ml (a total of 300 mg tremelimumab) concentrate in a Type I glass vial with an elastomeric stopper and a dark blue flip-off aluminum seal. Pack size of 1 single-dose vial.

Not all pack sizes may be marketed.

Marketing authorization holder

AstraZeneca AB, SE-151 85 Södertälje, Sweden

Marketing authorization dates and numbers

Date of first authorisation: 20 February 2023

Drugs

Drug	Countries
IMJUDO	Austria, Estonia, France, Croatia, Ireland, Italy, Japan, Lithuania, Romania, United Kingdom, United States

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.